Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ORAGENICS INCOGEN · Entity 8495 | President | September 19, 2024 | September 21, 2024 |
| Odyssey Health, Inc.ODYY · Entity 8618 | Director · President & CEO | June 28, 2024 | July 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ORAGENICS INC
Report date September 19, 2024 · Filed September 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.48 · Expires 2034-09-19 | Direct | 100,000 |
Reported balance
After 2024-09-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-09-19 · Grant · Acquired 100,000 · Balance 100,000 F1: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. The option shares vest immediately. The option exercise price is the Company's closing price on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. The option shares vest immediately. The option exercise price is the Company's closing price on the date of grant.
Odyssey Health, Inc.
Report date June 28, 2024 · Filed July 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.10 · Expires 2034-06-27 | Direct | 500,000 |
Reported balance
After 2024-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-28 · Grant · Acquired 500,000 · Balance 500,000 F1: The options vest 100,000 immediately; 100,000 vest on July 31, 2024; 100,000 vest on October 31, 2024; 100,000 vest on January 31, 2025; and 100,000 vest on April 30, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest 100,000 immediately; 100,000 vest on July 31, 2024; 100,000 vest on October 31, 2024; 100,000 vest on January 31, 2025; and 100,000 vest on April 30, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 19, 2024 Filed Sep 21, 2024 01:15 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantEmployee Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001493152-24-037733 · ownership.xml · derivative · entry 1 REDMOND J MICHAEL · CIK 0001200166 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-09-19 F1 · security: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. The option shares vest immediately. The option exercise price is the Company's closing price on the date of grant. F1 · shares: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. The option shares vest immediately. The option exercise price is the Company's closing price on the date of grant. F1 · derivative.exercise_date: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. The option shares vest immediately. The option exercise price is the Company's closing price on the date of grant. F1 · balance_after: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. The option shares vest immediately. The option exercise price is the Company's closing price on the date of grant. Read SEC document |
| June 28, 2024 Filed Jul 16, 2024 17:10 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.10 Strike: $0.10 | $50,000.00 |
DisclosureSEC source: 0001683168-24-004902 · ownership.xml · derivative · entry 1 REDMOND J MICHAEL · CIK 0001200166 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2034-06-27 F1 · shares: The options vest 100,000 immediately; 100,000 vest on July 31, 2024; 100,000 vest on October 31, 2024; 100,000 vest on January 31, 2025; and 100,000 vest on April 30, 2025. F1 · derivative.underlying_shares: The options vest 100,000 immediately; 100,000 vest on July 31, 2024; 100,000 vest on October 31, 2024; 100,000 vest on January 31, 2025; and 100,000 vest on April 30, 2025. F1 · balance_after: The options vest 100,000 immediately; 100,000 vest on July 31, 2024; 100,000 vest on October 31, 2024; 100,000 vest on January 31, 2025; and 100,000 vest on April 30, 2025. Read SEC document |
| December 29, 2023 Filed Jan 2, 2024 17:10 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.10 Strike: $0.10 | $50,000.00 |
DisclosureSEC source: 0001683168-24-000024 · ownership.xml · derivative · entry 1 REDMOND J MICHAEL · CIK 0001200166 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-12-28 F1 · shares: The options vest immediately and the exercise price is the closing price on the date of the grant, December 29, 2023 F1 · derivative.underlying_shares: The options vest immediately and the exercise price is the closing price on the date of the grant, December 29, 2023 F1 · balance_after: The options vest immediately and the exercise price is the closing price on the date of the grant, December 29, 2023 Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 22:09 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantEmployee Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0001493152-24-000124 · ownership.xml · derivative · entry 1 REDMOND J MICHAEL · CIK 0001200166 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-12-28 F1 · security: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, in connection with the Reporting Person's engagement to serve as the Company's President. 37,500 options shall vest on the December 28, 2023, the effective date of the Reporting Person's Employment Agreement with the Company (the "Effective Date"), 18,750 options shall vest on June 24, 2024, and 18,750 options shall vest on the first anniversary of the Effective Date, in each case provided the Reporting Person has remained in continuous employment with the Company through such dates. The option exercise price is the Company's closing price on the date of grant. F1 · shares: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, in connection with the Reporting Person's engagement to serve as the Company's President. 37,500 options shall vest on the December 28, 2023, the effective date of the Reporting Person's Employment Agreement with the Company (the "Effective Date"), 18,750 options shall vest on June 24, 2024, and 18,750 options shall vest on the first anniversary of the Effective Date, in each case provided the Reporting Person has remained in continuous employment with the Company through such dates. The option exercise price is the Company's closing price on the date of grant. F1 · derivative.exercise_date: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, in connection with the Reporting Person's engagement to serve as the Company's President. 37,500 options shall vest on the December 28, 2023, the effective date of the Reporting Person's Employment Agreement with the Company (the "Effective Date"), 18,750 options shall vest on June 24, 2024, and 18,750 options shall vest on the first anniversary of the Effective Date, in each case provided the Reporting Person has remained in continuous employment with the Company through such dates. The option exercise price is the Company's closing price on the date of grant. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 17:16 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GrantRestricted Stock Unit (Right to Buy) · Derivative | 400,000 | $0.30 Strike: $0.30 | $120,000.00 |
DisclosureSEC source: 0001683168-23-000193 · ownership.xml · derivative · entry 2 REDMOND J MICHAEL · CIK 0001200166 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500,000 Underlying: ODYY - Common Stock · 400,000 shares Expires not disclosed F1 · derivative.expiration_date: No expiration date Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 17:16 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GrantRestricted Stock Unit (Right to Buy) · Derivative | 100,000 | $0.30 Strike: $0.30 | $30,000.00 |
DisclosureSEC source: 0001683168-23-000193 · ownership.xml · derivative · entry 1 REDMOND J MICHAEL · CIK 0001200166 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,100,000 Underlying: ODYY - Common Stock · 100,000 shares Expires not disclosed F1 · derivative.expiration_date: No expiration date Read SEC document |
| September 02, 2022 Filed Sep 15, 2022 16:16 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GiftCommon Stock | 1,500,000 | $0.16 | $244,950.00 |
DisclosureSEC source: 0001683168-22-006423 · ownership.xml · nonDerivative · entry 1 REDMOND J MICHAEL · CIK 0001200166 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500,000 F1 · shares: Shares gifted are 500,000 shares of common stock gifted to Sean M Redmond; 500,000 shares of common stock gifted to Conor J. Redmond; 500,000 shares of common stock gifted to Devin P. Redmond. Read SEC document |
| May 19, 2022 Filed Jun 8, 2022 17:17 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GrantStock Option (Right to Buy) · Derivative | 375,000 | $0.30 Strike: $0.30 | $112,500.00 |
DisclosureSEC source: 0001683168-22-004242 · ownership.xml · derivative · entry 2 REDMOND J MICHAEL · CIK 0001200166 · Director · President/CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750,000 Underlying: Common Stock · 375,000 shares Expires 2032-05-18 Read SEC document |
| May 19, 2022 Filed Jun 8, 2022 17:17 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GrantStock Option (Right to Buy) · Derivative | 375,000 | $0.30 Strike: $0.30 | $112,500.00 |
DisclosureSEC source: 0001683168-22-004242 · ownership.xml · derivative · entry 1 REDMOND J MICHAEL · CIK 0001200166 · Director · President/CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,375,000 Underlying: Common Stock · 375,000 shares Expires 2032-05-18 Read SEC document |
| January 01, 2021 Filed Mar 1, 2021 19:46 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GrantRestricted Stock Unit (Right to Buy · Derivative | 3,000,000 | $0.18 Strike: $0.18 | $540,000.00 |
DisclosureSEC source: 0001683168-21-000747 · ownership.xml · derivative · entry 1 REDMOND J MICHAEL · CIK 0001200166 · Director · President/CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000,000 Underlying: ODYY - Common Stock · 3,000,000 shares Expires not disclosed F1 · derivative.exercise_date: The vesting of the RSU (Units) is as follows: 3,000,000 RSU vesting equally over 36 months, subject to the Grantee's continuous service through the applicable vesting date. If not forfeited, vesting of the Units will be accelerated and will vest in full immediately upon the closing of a Corporate Transaction, provided that Grantee provides Continuous Service to the Company through the date such Corporate Transaction is closed. Vested Units will be settled by delivering to Grantee a number of shares equal to the number of vested Units on the earlier of the date on which the Grantee's Continuous Service ends, or the closing of a Corporate Transaction. F2 · derivative.expiration_date: No expiration. Read SEC document |
| September 16, 2020 Filed Mar 1, 2021 19:46 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | OtherODYY - Common Stock Option · Derivative | 15,000,000 | $0.25 Strike: $0.25 | $3,750,000.00 |
DisclosureSEC source: 0001683168-21-000747 · ownership.xml · derivative · entry 2 REDMOND J MICHAEL · CIK 0001200166 · Director · President/CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000,000 Underlying: ODYY - Common Stock · 15,000,000 shares Expires not disclosed F3 · kind: Options not earned or vested and cancelled September 16, 2020 F2 · derivative.exercise_date: No expiration. F2 · derivative.expiration_date: No expiration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.